Mitogen-inducible gene-2 (MIG2) and migfilin expression is reduced in samples of human breast cancer
Ημερομηνία
2013Λέξη-κλειδί
Επιτομή
Background: Cell adhesion proteins that connect each cell to neighboring cells and the extracellular matrix play a fundamental role in metastasis. Mitogen-inducible gene-2 (MIG2), is a cell-matrix adhesion protein, which through migfilin, interacts with filamin-A, being linked to actin cytoskeleton. Aim: Recent studies have implicated both MIG2 and migfilin in cancer, but little is known regarding their expression in breast cancer. In this study, we investigated this topic. Materials and Methods: mRNA and protein expression was examined in 30 breast cancer samples and compared to that of normal adjacent tissue using real time-polymerase chain reaction (PCR) and western blotting. Results: Our results showed that expression of MIG2 and migfilin was significantly reduced in the majority of the breast cancer tissues compared to normal tissues regardless of metastatic status and disease stage. Conclusion: Both MIG2 and migfilin are down-regulated in breast cancer.
Collections
Related items
Showing items related by title, author, creator and subject.
-
Endocrine resistance and epigenetic reprogramming in estrogen receptor positive breast cancer
Dimitrakopoulos F.-I., Kottorou A., Tzezou A. (2021)Despite the enormous advances during the last three decades, breast cancer continues to be the most frequent type of cancer as well as one of the most frequent cancer-related causes of death in women. Therapeutic management ... -
Effects of TP53 and PIK3CA mutations in early breast cancer: a matter of co-mutation and tumor-infiltrating lymphocytes
Kotoula V., Karavasilis V., Zagouri F., Kouvatseas G., Giannoulatou E., Gogas H., Lakis S., Pentheroudakis G., Bobos M., Papadopoulou K., Tsolaki E., Pectasides D., Lazaridis G., Koutras A., Aravantinos G., Christodoulou C., Papakostas P., Markopoulos C., Zografos G., Papandreou C., Fountzilas G. (2016)The purpose of this study is to investigate whether the outcome of breast cancer (BC) patients treated with adjuvant chemotherapy is affected by co-mutated TP53 and PIK3CA according to stromal tumor-infiltrating lymphocytes ... -
TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting
Fountzilas G., Giannoulatou E., Alexopoulou Z., Zagouri F., Timotheadou E., Papadopoulou K., Lakis S., Bobos M., Poulios C., Sotiropoulou M., Lyberopoulou A., Gogas H., Pentheroudakis G., Pectasides D., Koutras A., Christodoulou C., Papandreou C., Samantas E., Papakostas P., Kosmidis P., Bafaloukos D., Karanikiotis C., Dimopoulos M.-A., Kotoula V. (2016)Background: We investigated the impact of PIK3CA and TP53 mutations and p53 protein status on the outcome of patients who had been treated with adjuvant anthracycline-taxane chemotherapy within clinical trials in the pre- ...